Cytokinetics

Intern - Pharmacology

South San Francisco, California, United States

$22,000 – $45,000Compensation
InternshipExperience Level
Full TimeJob Type
UnknownVisa
Biotechnology, HealthcareIndustries

Requirements

Candidates should possess prior experience in basic lab skills such as pipetting and preparing physiological buffers, excellent communication skills, basic computer skills including data management and presentation, and coursework in biology and physiology. Prior animal handling experience is desirable, with a willingness to learn to handle rodents required.

Responsibilities

The intern will work closely with a Pharmacology Researcher to conduct and manage in vivo and in vitro experiments related to the efficacy of novel small molecule compounds for potential therapies of muscular degenerative diseases, contributing to meaningful projects within the biopharmaceutical industry.

Skills

pipetting
physiological buffers
data management
data presentation
animal handling
rodent handling

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Key Metrics

South San Francisco, CaliforniaHeadquarters
1998Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Risks

Increased competition could impact market share and profitability.
Potential delays in clinical trials could hinder drug commercialization.
Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
The company has a robust pipeline including omecamtiv mecarbil and aficamten.
Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.
Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI